¼¼°èÀÇ Ç÷Àå À¯µµÃ¼ ½ÃÀå : ±âȸ ¹× Àü·«(-2033³â)
Blood Plasma Derivatives Global Market Opportunities And Strategies To 2033
»óǰÄÚµå : 1486801
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 327 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,000 £Ü 5,690,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,000 £Ü 8,535,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,380,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Ç÷Àå À¯µµÃ¼ ½ÃÀåÀº 2018³â 317¾ï 1,270¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2023³â±îÁö ¿¬Æò±Õ 8.0% ÀÌ»ó ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç÷¿ìº´ À¯º´·ü Áõ°¡

Ç÷¿ìº´ À¯º´·ü Áõ°¡´Â Áö±Ý±îÁö Ç÷Àå À¯µµÃ¼ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇß½À´Ï´Ù. Ç÷¿ìº´Àº Ç÷¾×ÀÌ Á¦´ë·Î ÀÀ°íµÇÁö ¾Ê´Â °ÍÀÌ Æ¯Â¡ÀÎ À¯Àü¼º ÁúȯÀÔ´Ï´Ù. ÀÌ ÁúȯÀº ÀϹÝÀûÀ¸·Î À¯Àü¼ºÀ̸ç ÁÖ·Î ³²¼º¿¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù. Ç÷Àå À¯µµÃ¼´Â ÁöÇ÷À» ȸº¹Çϰí ÃâÇ÷ ¿¡ÇǼҵ带 È¿°úÀûÀ¸·Î ¿¹¹æ ¶Ç´Â Ä¡·áÇÏ´Â µ¥ ÇÊ¿äÇÑ ÀÀ°í ÀÎÀÚ¸¦ Á¦°øÇÔÀ¸·Î½á Ç÷¿ìº´ °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. À¯ÀüÀÚ ÀçÁ¶ÇÕ Ç÷¾×ÀÀ°íÀÎÀÚ Á¦Á¦´Â ¾ÈÀü¼º°ú °ø±Þ ¾ÈÁ¤¼ºÀÌ Çâ»óµÇ¾úÁö¸¸, ƯÈ÷ À¯ÀüÀÚ ÀçÁ¶ÇÕ Á¦Á¦¸¦ ±¸Çϱ⠾î·Á¿î Áö¿ªÀ̳ª À¯ÀüÀÚ ÀçÁ¶ÇÕ Á¦Á¦¿¡ ´ëÇÑ ¾ïÁ¦Á¦¸¦ °¡Áø ȯÀÚ¿¡°Ô´Â Ç÷Àå À¯·¡ ÀÀ°íÀÎÀÚ°¡ ¿©ÀüÈ÷ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ç÷Àå À¯·¡ Á¦Á¦´Â Ç÷¾× ¸Å°³ º´¿øÃ¼ ÀüÆÄ¿¡ ´ëÇÑ ¿ì·Á¿¡µµ ºÒ±¸Çϰí Ç÷Àå À¯·¡ Á¦Á¦´Â Ç÷¿ìº´ Ä¡·á¸¦À§ÇÑ ºñ¿ë È¿À²ÀûÀ̰í Á¢±ÙÇϱ⠽¬¿î ¿É¼ÇÀ» °è¼Ó Á¦°øÇÏ¿© ÃâÇ÷ ¿¡ÇǼҵåÀÇ È¿°úÀûÀÎ °ü¸®¿Í ÁöÇ÷ ȸº¹À» º¸ÀåÇÕ´Ï´Ù. ¿¡ µû¸£¸é ¹Ì±¹ ³²¼º 10¸¸ ¸í´ç Ç÷¿ìº´ B´Â 3.7¸í, Ç÷¿ìº´ A´Â 12¸íÀ̾ú½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹¿¡¼­´Â ³²¼º Ãâ»ý¾Æ 5,617¸í´ç 1¸í, ³²¼º Ãâ»ý¾Æ 19,283¸í´ç 1¸íÀÌ Ç÷¿ìº´ BÇü Ç÷¿ìº´À» ¾Î°í ÀÖ½À´Ï´Ù. µû¶ó¼­ Ç÷¿ìº´ À¯º´·ü Áõ°¡°¡ Ç÷Àå À¯µµÃ¼ ½ÃÀåÀ» °ßÀÎÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¸ñÂ÷

Á¦3Àå Ç¥ ¸®½ºÆ®

Á¦4Àå ±×·¡ÇÁ ¸®½ºÆ®

Á¦5Àå º¸°í¼­ ±¸¼º

Á¦6Àå ½ÃÀå Æ¯Â¡

Á¦7Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦8Àå Ç÷Àå À¯µµÃ¼ ½ÃÀå : °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦9Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¼ºÀå

Á¦10Àå ¼¼°èÀÇ Ç÷Àå À¯µµÃ¼ ½ÃÀå : ¼¼ºÐÈ­

Á¦11Àå Ç÷Àå À¯µµÃ¼ ½ÃÀå : Áö¿ª/±¹°¡º° ºÐ¼®

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦13Àå ¼­À¯·´ ½ÃÀå

Á¦14Àå µ¿À¯·´ ½ÃÀå

Á¦15Àå ºÏ¹Ì ½ÃÀå

Á¦16Àå ³²¹Ì ½ÃÀå

Á¦17Àå Áßµ¿ ½ÃÀå

Á¦18Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦19Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦20Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦21Àå °æÀï º¥Ä¡¸¶Å·

Á¦22Àå °æÀï ´ë½Ãº¸µå

Á¦23Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦24Àå ±âȸ¿Í Àü·«

Á¦25Àå Ç÷Àå À¯µµÃ¼ ½ÃÀå : °á·Ð°ú Á¦¾È

Á¦26Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Blood plasma derivatives are medical products derived from human blood plasma. Plasma is the liquid component of blood that remains after cells (red blood cells, white blood cells and platelets) are removed. Plasma derivatives are typically obtained through a process called fractionation, where plasma proteins are separated and purified from the collected plasma.

The blood plasma derivatives market consists of sales, by entities (organizations, sole traders and partnerships), of products derived from the plasma portion of human blood.

The global blood plasma derivatives market was valued at $31,712.7 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 8.0%.

Rise In Hemophilia Prevalence

The rise in hemophilia prevalence drove the growth of the blood plasma derivatives market during this historic period. Hemophilia is a genetic disorder characterized by the inability of the blood to clot properly. This condition is typically inherited and primarily affects males. Blood plasma derivatives play a crucial role in the management of hemophilia by providing the necessary clotting factors to restore hemostasis and prevent or treat bleeding episodes effectively. While recombinant clotting factor products offer enhanced safety profiles and supply stability, plasma-derived factors remain crucial, especially in regions with limited access to recombinant products or for patients with inhibitors against them. Despite concerns regarding blood-borne pathogen transmission, plasma-derived products continue to provide a cost-effective and accessible option for treating hemophilia, ensuring the effective management of bleeding episodes and restoration of hemostasis. In August 2022, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, for every 100,000 American males, there were 3.7 instances of hemophilia B and 12 cases of hemophilia A, respectively. Moreover, it affects 1 in 5,617 male births in the US and 1 in 19,283 male births with hemophilia B. Therefore, the rise in hemophilia prevalence drove the blood plasma derivatives market.

Increasing Investments To Expand Blood Plasma Production Capabilities

Companies in the blood plasma derivatives market are focusing on increasing their investments to capitalize on growth opportunities and contribute to long-term sustainability and profitability. For example, in September 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, invested close to $330 million in expanding its plasma-derived therapy production. This investment aims to enhance access to treatments for rare and complex chronic diseases, such as primary immunodeficiencies and rare conditions like hereditary angioedema and bleeding disorders. Furthermore, in March 2023, CSL Plasma, a US-based plasmapheresis company, invested $470 million to establish a new plasma fractionation facility at its site located in Marburg to expand its production capabilities and enhance its commitment to delivering on its promise to patients.

The global blood plasma derivatives market is fairly concentrated, with a large number of players operating in the market. The top ten competitors in the market made up to 22.6% of the total market in 2022.

Blood Plasma Derivatives Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global blood plasma derivatives market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Where is the largest and fastest-growing market for blood plasma derivatives? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The blood plasma derivatives market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider blood plasma derivatives market; and compares it with other markets.

The report covers the following chapters

Markets Covered:

Table of Contents

1 Executive Summary

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

7 Major Market Trends

8 Blood Plasma Derivatives Market - Macro Economic Scenario

9 Global Market Size and Growth

10 Global Blood Plasma Derivatives Market Segmentation

11 Blood Plasma Derivatives Market, Regional and Country Analysis

12 Asia-Pacific Market

13 Western Europe Market

14 Eastern Europe Market

15 North America Market

16 South America Market

17 Middle East Market

18 Africa Market

19 Competitive Landscape And Company Profiles

20 Blood Plasma Derivatives Market Other Major And Innovative Companies

21 Competitive Benchmarking

22 Competitive Dashboard

23 Key Mergers And Acquisitions

24 Opportunities And Strategies

25 Blood Plasma Derivatives Market, Conclusions And Recommendations

26 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â